Intrexon | XON - Operating Expenses


Intrexon reported $61.56M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agenus USD 19.81M 293.94M Dec/2025
Alaunos Therapeutics USD 1.19M 148K Sep/2025
Amgen USD 5.9B 773M Dec/2025
Anika Therapeutics USD 29.97M 116.84M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
MacroGenics USD 53.32M 13.68M Dec/2025
MannKind USD 119.64M 56.29M Dec/2025
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Thermo Fisher Scientific USD 9.91B 867M Dec/2025
Veracyte USD 116M 7.24M Dec/2025
Xencor USD 81.86M 13.35M Dec/2025